| Research Collaborator |
YOSHIZAWA Go 大阪大学, 医学系研究科, 准教授 (19526677)
TERADA Yoh 特定非営利活動法人知的財産研究推進機構(PRIPTokyo)プロジェクトメンバー, 特定非営利活動法人ASrid
MASATOSHI Iwasaki 特定非営利活動法人知的財産研究推進機構(PRIPTokyo)プロジェクトメンバー, 特定非営利活動法人ASrid
KUNIHIRO Nishimura 特定非営利活動法人知的財産研究推進機構(PRIPTokyo)プロジェクトメンバー, 特定非営利活動法人ASrid
MASASHI Suganuma 一般社団法人こいのぼり, 特定非営利活動法人ASrid
TARO Inaba 一般社団法人こいのぼり, 特定非営利活動法人ASrid
|
|---|
| Budget Amount *help |
¥6,591,364 (Direct Cost: ¥5,070,280、Indirect Cost: ¥1,521,084)
Fiscal Year 2014: ¥853,788 (Direct Cost: ¥656,760、Indirect Cost: ¥197,028)
Fiscal Year 2013: ¥853,788 (Direct Cost: ¥656,760、Indirect Cost: ¥197,028)
Fiscal Year 2012: ¥853,788 (Direct Cost: ¥656,760、Indirect Cost: ¥197,028)
Fiscal Year 2011: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2010: ¥1,300,000 (Direct Cost: ¥1,000,000、Indirect Cost: ¥300,000)
Fiscal Year 2009: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|
|---|
| Outline of Final Research Achievements |
This research is focusing to all human recourses / stakeholders related to orphan drug/rare disease (NANBYO) area. The purpose of this research is study for the importance of collaboration and corporation among them and development of concrete way for providing valuable knowledge about this field.
In this research, the team had considered; 1) the survey for NANBYO patients and patient groups in Japan, 2) Study for rare disease situation in the US. The team has also considered; 3) organizing the international conference (International Conference for Rare Disease and Orphan Drugs), 4) organizing workshop for all stakeholders in this field, and 5) establishment Patient Advocacy organizations (for specific disease and for all NANBYO area). Almost of these activities are the first challenges in Japan, and increasing valuable opportunities to connect with/among all stakeholders.
|
